a public good project by the
Synthesis
Company
of California

© 2026

Alison Donald | doi.page

0 works0 citations0 h-index

Alison Donald

University of Calgary(CA)NeuroDevelopment Center(US)Hotchkiss Brain Institute(CA)

Publications by Year

Research Areas

Chronic Obstructive Pulmonary Disease (COPD) Research, Asthma and respiratory diseases, Respiratory Support and Mechanisms, Inhalation and Respiratory Drug Delivery, Meta-analysis and systematic reviews

Most-Cited Works

→ Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies(2015)74 cited
→ Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials(2014)72 cited
→ CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial(2020)68 cited
→ Empirical assessment suggests that existing evidence could be used more fully in designing randomized controlled trials(2010)65 cited
→ An encouraging assessment of methods to inform priorities for updating systematic reviews(2008)29 cited
→ A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 &micro;g on health-related quality of life in patients with COPD(2016)28 cited

→ Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Inhaled Once-Daily Umeclidinium in Healthy Adults Deficient in CYP2D6 Activity: A Double-Blind, Randomized Clinical Trial(2013)14 cited

→ Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial(2013)14 cited

→ Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK(2020)13 cited

→ Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study(2018)13 cited